Wales approve pancreatic cancer drug for use despite NICE rejection in England
March 18, 2016Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval
Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
Study data supports switch to Celltrion’s Remicade biosimilar
March 18, 2016Research and Development
Celltrion and distribution partner Mundipharma have presented study data supporting switching irritable bowel disease (IBD) patients from Remicade to biosimilar …
Indian govt set to ban 1,200 fixed-dose combination drugs, reports
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abbott Laboratories, Pfizer, cough drug, pharma
Indian regulators are set to ban an additional 1,200 fixed-dose combinations, sent for probe by Drug Controller General of India …
OncoMed initiates Phase Ib immuno-oncology combination clinical trial
March 18, 2016Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
Allergan files ANDA for generic version of Celgene’s breast cancer treatment
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic
Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …
Gilead cancer boss departs after safety concerns halt Zydelig trials
March 18, 2016Medical Communications, Research and Development Gilead Sciences, zydelig
In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …
Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma
March 18, 2016Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma
Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy …
FDA approves Breckenridge’s generic of Pfizer’s anti-epilepsy drug
March 18, 2016Research and Development, Sales and Marketing FDA, Neurontin, Pfizer, anti-epilepsy, approval, breckenridge, gabapentin, tris pharma
Breckenridge Pharmaceutical Inc. has announced that their generic of Pfizer’s anti-epilepsy drug Neurontin (gabapentin) has been approved by the US …
Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi
March 17, 2016Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis
US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …
Vitae Pharma soars on positive mid-stage trial results for psoriasis drug
March 17, 2016Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research
Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …
Building trust and loyalty in medical communications – London-based agency reveal their approach
March 17, 2016Medical Communications Synergy Vision, graduate recruitment, medical communications, medical communications agency, recruitment, retention
There has always been a high turnover of staff within the medical communications industry – a recent survey on the …
Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million
March 17, 2016Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition
Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to …
FDA approves Bayer haemophilia A drug Kovaltry
March 17, 2016Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound
Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
Chugai receive orphan drug status for autoimmune disease treatment
March 17, 2016Manufacturing and Production, Medical Communications, Research and Development chuagi, systemic scleroderma, tocilizumab
Chugai Pharmaceutical Co. (TYO: 4519) has received a notification of orphan drug designation, from the Japanese minister of health, labour …
Baxter to cut stake in Baxalta
March 17, 2016Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter
Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …
Sir Andrew Witty announces decision to step down as CEO of GSK
March 17, 2016Medical Communications, Research and Development Andrew Witty, GSK, GlaxoSmithKline, Neil Woodford, Sir Andrew Witty, Witty, gsk break up, gsk split, retirement, steps down
Sir Andrew Witty has announced his decision to retire from his role as chief executive officer of pharmaceutical giant, GlaxoSmithKline …
GSK’s asthma drug meets primary goal in safety study for children
March 17, 2016Research and Development Advair Diskus, GSK, asthma, drug trial
GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children. …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
Vectura agree £441m merger with Skyepharma
March 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Skyepharma, UK, biotech, merger, vectura
Vectura (LON: VEC) and Skyepharma (LON: SKP), two UK-based pharma companies, have joined together in a deal worth £441m. The …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
